Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

Core Viewpoint - Inovio Pharmaceuticals (INO) has experienced significant selling pressure, resulting in an 11.4% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - INO's current RSI reading is 25.47, suggesting that the heavy selling may be nearing exhaustion, potentially leading to a price rebound [5] Group 2: Fundamental Analysis - There is a strong consensus among sell-side analysts to raise earnings estimates for INO, with a 33.4% increase in the consensus EPS estimate over the last 30 days [7] - INO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a favorable outlook for a potential turnaround [8]